In Silico Computational Screening of Kabasura Kudineer - Official Siddha Formulation and JACOM - Novel Herbal Coded Formulation Against SARS-CoV-2 Spike protein
52 Pages Posted: 13 Apr 2020
Date Written: April 13, 2020
Siddha Medicine is a valuable therapeutic choice which is classically used for treating viral respiratory infections, this principle of medicine is proven to contain antiviral compounds. In this study, we executed the molecular docking studies for Phytoconstituents of Siddha official formulation Kabasura Kudineer which is used in treating viral fever and respiratory diseases and a Novel Herbal Preparation - JACOM against the ongoing pandemic of novel coronavirus disease causative agent SARS-CoV-2 Spike protein. Further, we also conducted prediction studies on the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates using pkCSM and SwissADME web servers. Totally 37 compounds were screened, of these 9 compounds showed high binding efficiency. Based on these, we proposed the new formulation called as “SNACK –V”.
Note: Funding: This work is supported by CCRS, Chennai and Salem microbes Private Ltd, Salem.
Conflict of Interest: The authors declare no Conflict of interest.
Ethical Approval: We not used any animals in the study and not carried out human trials. Hence, no need for ethical clearance.
Keywords: COVID-19, SARS-CoV-2 Spike protein, Kabasura Kudineer, JACOM, Molecular docking, ADMET, Siddha Medicine, SNACK-V
Suggested Citation: Suggested Citation